Yashar William M, Estabrook Joseph, Holly Hannah D, Somers Julia, Nikolova Olga, Babur Özgün, Braun Theodore P, Demir Emek
Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA.
Division of Oncologic Sciences, Department of Medicine, Oregon Health & Science University, Portland, OR 97239, USA.
iScience. 2024 Feb 5;27(3):109124. doi: 10.1016/j.isci.2024.109124. eCollection 2024 Mar 15.
Dysregulation of normal transcription factor activity is a common driver of disease. Therefore, the detection of aberrant transcription factor activity is important to understand disease pathogenesis. We have developed Priori, a method to predict transcription factor activity from RNA sequencing data. Priori has two key advantages over existing methods. First, Priori utilizes literature-supported regulatory information to identify transcription factor-target gene relationships. It then applies linear models to determine the impact of transcription factor regulation on the expression of its target genes. Second, results from a third-party benchmarking pipeline reveals that Priori detects aberrant activity from 124 single-gene perturbation experiments with higher sensitivity and specificity than 11 other methods. We applied Priori and other top-performing methods to predict transcription factor activity from two large primary patient datasets. Our work demonstrates that Priori uniquely discovered significant determinants of survival in breast cancer and identified mediators of drug response in leukemia.
正常转录因子活性的失调是疾病的常见驱动因素。因此,检测异常转录因子活性对于理解疾病发病机制很重要。我们开发了Priori,一种从RNA测序数据预测转录因子活性的方法。与现有方法相比,Priori有两个关键优势。首先,Priori利用文献支持的调控信息来识别转录因子-靶基因关系。然后应用线性模型来确定转录因子调控对其靶基因表达的影响。其次,来自第三方基准测试管道的结果表明,Priori在124个单基因扰动实验中检测异常活性的灵敏度和特异性高于其他11种方法。我们应用Priori和其他表现最佳的方法从两个大型原发性患者数据集中预测转录因子活性。我们的工作表明,Priori独特地发现了乳腺癌生存的重要决定因素,并确定了白血病药物反应的介质。